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Abstract
Objective To determine the effect of clinical scores that predict
streptococcal infection or rapid streptococcal antigen detection tests
compared with delayed antibiotic prescribing.
Design Open adaptive pragmatic parallel group randomised controlled
trial.
Setting Primary care in United Kingdom.
Patients Patients aged ≥3 with acute sore throat.
Intervention An internet programme randomised patients to targeted
antibiotic use according to: delayed antibiotics (the comparator group
for analyses), clinical score, or antigen test used according to clinical
score. During the trial a preliminary streptococcal score (score 1, n=1129)
was replaced by a more consistent score (score 2, n=631; features:
fever during previous 24 hours; purulence; attends rapidly (within three
days after onset of symptoms); inflamed tonsils; no cough/coryza
(acronym FeverPAIN).
Outcomes Symptom severity reported by patients on a 7 point Likert
scale (mean severity of sore throat/difficulty swallowing for days two to
four after the consultation (primary outcome)), duration of symptoms,
use of antibiotics.
Results For score 1 there were no significant differences between
groups. For score 2, symptom severity was documented in 80% (168/207
(81%) in delayed antibiotics group; 168/211 (80%) in clinical score group;
166/213 (78%) in antigen test group). Reported severity of symptoms
was lower in the clinical score group (−0.33, 95% confidence interval
−0.64 to −0.02; P=0.04), equivalent to one in three rating sore throat a
slight versus moderate problem, with a similar reduction for the antigen
test group (−0.30, −0.61 to −0.00; P=0.05). Symptoms rated moderately
bad or worse resolved significantly faster in the clinical score group
(hazard ratio 1.30, 95% confidence interval 1.03 to 1.63) but not the
antigen test group (1.11, 0.88 to 1.40). In the delayed antibiotics group,
75/164 (46%) used antibiotics. Use of antibiotics in the clinical score
group (60/161) was 29% lower (adjusted risk ratio 0.71, 95% confidence
interval 0.50 to 0.95; P=0.02) and in the antigen test group (58/164) was
27% lower (0.73, 0.52 to 0.98; P=0.03). There were no significant
differences in complications or reconsultations.
Correspondence to: P Little p.little@soton.ac.uk
Extra material supplied by the author (see http://www.bmj.com/content/347/bmj.f5806?tab=related#webextra)
Appendix 1: Development of scores; flow chart and results for score 1
Appendix 2: Sample size calculations
Appendix 3: Evidence of selection and attrition bias
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5806 doi: 10.1136/bmj.f5806 (Published 10 October 2013) Page 1 of 10
Research
RESEARCH
Conclusion Targeted use of antibiotics for acute sore throat with a
clinical score improves reported symptoms and reduces antibiotic use.
Antigen tests used according to a clinical score provide similar benefits
but with no clear advantages over a clinical score alone.
Trial registration ISRCTN32027234
Introduction
Most patients presenting with acute sore throat still receive
antibiotics,1 despite a Cochrane review documenting onlymodest
symptomatic benefit.2 The review also documents that though
antibiotics probably prevent complications, they are rare.2 This
is supported by recent ecological data3 and routine datasets,1 4
which confirm that complications are not common in routine
practice.
Sore throat is one of the respiratory infections for which there
are several reasonable diagnostic strategies for targeting
antibiotics: rapid streptococcal antigen detection tests (RADTs)
are one of the commonest near patient tests in clinical use
internationally, and clinical scores to predict streptococcal
infection are also widely advocated and used either alone or in
combination with the antigen test.5-8 Use of clinical scores such
as the Centor criteria (which were designed to predict the
presence of Lancefield group A β-haemolytic streptococci) or
antigen tests have the potential to better target antibiotics,
prevent progression of the illness and complications, improve
symptom control, and reduce overall antibiotic use compared
with empirical management strategies such as delayed
prescribing or no offer of antibiotics.9 There is, however, a
paucity of evidence for clinical scores for most of these
outcomes: one Canadian trial suggested that rapid antigen tests
but not the Centor criteria modified antibiotic prescribing, but
the trial was small and did not report on important patient
outcomes such as symptom control or progression of illness.10
Further evidence is needed to confirm whether the use of rapid
antigen tests or clinical scores can modify antibiotic use and
patient outcomes.
We previously performed in vitro and diagnostic phases of this
project to provide evidence for choosing a valid and widely
available rapid antigen test.11We showed that Lancefield groups
C and G streptococci were presenting in a similar manner to
group A streptococci and developed a clinical score to predict
the presence of Lancefield Group A, C, and G streptococci.
Methods
We compared three strategies for limiting or targeting antibiotic
use in patients with sore throat: delayed antibiotic prescribing,
the use of a clinical score designed to identify streptococcal
infection, and the targeted use of rapid antigen tests according
to the clinical score. The trial was also adapted after agreement
from the funders and ethics committee. At the start of the trial
we used score 1 (n=1129). During the trial, however, when a
more consistent score became available based on separate
diagnostic studies, we used the second score (score 2 (acronym
FeverPAIN), n=631). We have presented the results for score
2 here, with the results for score 1 in appendix 1. We did not
use analysis of the results for score 1 in making the decision to
adapt the trial.
Rationale for changing the clinical scores
during the trial: separate diagnostic studies
We used two diagnostic studies in patients not involved in the
trial (combined n=1107) to develop the clinical scores to predict
streptococcal infection with Lancefield C, G, and A groups. The
initial plan was to follow a traditional “sequential” approach of
developing a score in one cohort, then validating it a second
cohort to get round the problem of overfitting. The first part of
the trial used a clinical score developed from the first diagnostic
study (score 1; area under the receiver operating characteristics
curve (AUC) of 0.76). The second diagnostic study, however,
showed considerably reduced discrimination for score 1 (AUC
0.65) because of inconsistent performance of the variables
making up score 1. We therefore used a modified approach to
generate a second score (score 2; acronym FeverPAIN), using
data from both diagnostic studies and corrected for the problem
of overfitting by using bootstrapping techniques. Variables were
included in the second score only if they were significant in
univariate analysis of both diagnostic studies and in the
multivariate analysis of at least one of the two diagnostic studies.
Score 2 hadmoderate discrimination in both cohorts (AUC first
cohort 0.74, second 0.71), better than the Centor criteria (0.72
and 0.65, respectively). Unlike the Centor criteria, score 2
(FeverPAIN) performedwell in identifying a substantial number
of participants at low risk of streptococcal infection. Although
the second score had internal validation with bootstrapping of
the estimates, ideally further external validation is needed. The
features of score 2 were: fever during previous 24 hours;
purulence; attend rapidly (within three days); inflamed tonsils;
no cough/coryza (acronym FeverPAIN)) (see appendix 1 for
further details).
Trial recruitment
Health professionals, mainly general practitioners but also triage
practice nurses, recruited patients presenting with acute sore
throat in general practices in south and central England.
Inclusion criteria
Included patients were people aged ≥3 presenting with acute
sore throat (two weeks or less of sore throat) and an abnormal
looking throat—that is, erythema and/or pus—as in our previous
studies in primary care12). Exclusion criteria were non-infective
causes of sore throat (such as aphthous ulceration, candida,
drugs) and inability of patient or parent/guardian to consent
(such as dementia, uncontrolled psychosis).
Baseline clinical measure
The recruiting health professional completed clinical details at
baseline:
• Temperature (using Tempadot thermometers)
• The presence and severity of baseline symptoms (sore
throat, difficulty swallowing, fever during the illness, runny
nose, cough, feeling unwell, diarrhoea, vomiting, headache,
muscles ache, abdominal pain, sleep disturbance,
interference with normal activities) on 4 point Likert scales
(none, a slight problem, a moderately bad problem, a bad
problem), and the presence of signs (pus, nodes, tender
nodes, raised temperature).13-16
Clinicians were asked to complete non-recruitment logs, but,
because of time pressures in acute clinics, there was poor
compliance. Clinicians were also asked to document the
commonest reasons why patients were not approached and why
they declined in an end of study questionnaire.
Randomisation
After the baseline assessment, patients were individually
randomised with a web based computer randomisation service
to one of three groups (see below). Randomisation used
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permuted block sizes of 3, 6, 9, and 12, which were also
randomly chosen. Originally the protocol specified stratification
by clinician’s belief in the likelihood of bacterial infection, but
after discussion with the funder this was omitted.
All patients were advised to use regular analgesia (paracetamol
or ibuprofen, or both).
Allocated groups
Delayed antibiotics (control)
A prescription was prepared and left in reception, with advice
to the patient to collect the prescription after three to five days
if symptoms were not starting to settle or were getting
considerably worse.17This strategy previously resulted in similar
rates of antibiotic use and beliefs compared with no offer of
antibiotics and reduced reconsultation more effectively.18 19 It
has been incorporated into routine practice in the United
Kingdom with no increase in complications of sore throat.20
Clinical score
The clinical score (FeverPAIN) was applied, and antibiotics
were not offered to those with low scores (0/1). Immediate
antibiotics were offered for those with high scores (≥4, an
estimated 63% streptococci based on the diagnostic studies)
and delayed antibiotics for those with intermediate scores (2 or
3, 39% streptococci).
Rapid antigen detection test group
The clinical score was used in all patients randomised to the
rapid antigen test group. Those with low clinical scores (0/1)
were not offered antibiotics or a rapid antigen test (<20%
streptococci), those with a score of 2 (33% streptococci) were
offered a delayed prescription, and those with higher scores
(≥3, 55% streptococci) underwent a rapid antigen test on surgery
premises. After the test, patients with negative results were not
offered antibiotics. The IMI test pack RADT was used based
on in vitro performance and ease of use.
Data collection
Patients were blind to the precise details of the groups being
tested, but the open design made full blinding impossible. The
research team who collected data (by phone or notes review)
were blind to group as far as possible, but details of patient
management were available in the notes. No changes in planned
outcome measures were made after the start of the trial.
Daily diary
Patients completed a symptom diary each night until symptoms
resolved or up to 14 nights.12 17 Each symptomwas scored (0=no
problem to 6=as bad as it could be): sore throat, difficulty
swallowing, feeling unwell, fevers, sleep disturbance. Patients
took their temperature with a disposable thermometer
(TempaDot, 3M, Bracknell) as in previous studies.12 21 If a diary
was not received by three weeks, a brief questionnaire was sent
to document key outcomes, and then a telephone call if the brief
questionnaire was not received.
Outcomes
Primary outcome: symptom severity—This was the mean score
of sore throat and difficulty swallowing for the two to four days
after the consultation, when patients rate their sore throat at its
worst, and is internally reliable (Cronbach’s α=0.92).
Duration of illness—Before analysis the trial management team
agreed that illness rated moderately bad or worse19 was more
important in decision making for both patients and clinicians
than the duration of milder symptoms until complete resolution.
Antibiotic use—Patients reported antibiotic use, which agrees
well with the documented collection of delayed prescriptions.3
Side effects—Diarrhoea and skin rash were documented in the
diary and from review of the notes.
Medicalising beliefs—Patients’ belief in the importance of
seeing the doctor for future episodes was recorded on reliable
Likert scales.17
Notes were reviewed to document subsequent episodes of
infection, time to return for these episodes, complications, and
economic data.12 The available follow-up time varied from one1
month to two years.
Sample size calculations—We used the NQUERY multiple
group sample size programme for three groups. For a 0.33
standardised effect size between the rapid antigen test group
and the other groups (assuming both control groups are 0.33
SD higher than the rapid antigen test group), we estimated that
we needed a minimum of 134 per group (for α=0.05, β=0.2) or
495 allowing for 20% loss to follow-up (which was the target
for the second phase of the trial). For α=0.01 and β=0.1, we
would need 242 per group, or 909 patients in total, allowing for
20% loss to follow-up of diary information.17 19 The SD of 0.33
is equivalent to about half of the patients rating sore throat a
mild rather than a moderately bad problem.19 (See appendix 2
for sample size calculations for other outcomes).
Analysis
The trial management team (blind to study group) finalised the
analysis plan before performing the analysis. Analysis of
covariance was performed for the severity scores and Cox
regression for the duration of symptoms rated moderately bad
or worse. Proportional hazards assumptions for Cox regression
were checked graphically and deemed appropriate. Logistic
regression was used for dichotomised outcomes (such as beliefs
and return to the surgery, adjusted for follow-up time). Odds
ratios were converted to risk ratios.22 The models controlled for
baseline severity (a strong predictor of outcome) and potential
confounders (in this case fever during the past 24 hours).
Intention to treat analysis was based on complete datasets, given
the problem of imputingmodest differences for rapidly changing
symptomatic outcomes. Although a per protocol analysis was
initially considered, given the pragmatic nature of the study it
was difficult to operationalise what per protocol might mean,
so no per protocol analysis was performed. Secondary analyses
were also performed at the suggestion of the referees, with
adjustment for practice as a covariate (that is, adjusting for
confounding by practice) and also with practice as a cluster
variable (that is, adjusting for clustering by practice). Selection
bias was assessed by comparing clinical features to the previous
diagnostic study and with a parallel observational cohort with
the same clinical proforma (theMRCDESCARTE study, which
recruited more than 10 000 patients). No interim analysis was
performed, no subgroups were specified in advance. The study
team agreed in advance that if there were significant differences
between the two scores (based on interaction terms in the
models), we would present the score 2 results separately as the
main results, with score 1 results documented in an appendix.
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Results
Patients presenting in primary care were recruited from 23
October 2008 until 18 April 2011 from 48 practices overall, of
which 46 practices recruited for the first part of the trial and 21
practices recruited for the second part of the trial (figure⇓ for
score 2 and appendix 1 for score 1). These practices recruited
1760 patients: 1129 in the first part of the trial and 631 in the
second part (which reached the minimum sample size for the
primary outcome but not the intended higher sample size). As
there was clear evidence of differential effectiveness, with score
2 performing better than score 1 (see appendix 1 for score 1
results), we have presented the results from the second part of
the trial only.
Group characteristics
Most baseline characteristics of the groups were similar (table
1⇓) except that fever reported in the past 24 hours was more
common in the clinical score group. As fever modestly changed
the estimates, all results control for fever in addition to baseline
severity of sore throat and difficulty swallowing. Female patients
were slightly less common in the clinical score group, but
inclusion of sex in the model made no difference to the estimates
and so results are presented without adjustment for sex.
Primary outcome: symptom severity (mean
score of soreness and difficulty swallowing
in days 2-4)
Compared with the control group, there were greater
improvements in symptom severity for both the clinical score
group (−0.33, 95% confidence interval −0.64 to −0.02) and the
rapid antigen test group (−0.30, −0.61 to 0.004)—that is, about
one third of a point, equivalent to one person in three rating sore
throat and difficulty swallowing a slight rather than amoderately
bad problem (table 2⇓).
Secondary outcomes
Duration of moderately bad symptoms
In the delayed prescribing (control) group, symptoms rated
moderately bad or worse lasted a median of 5.0 days. Compared
with the delayed antibiotics group, symptom resolution was
significantly faster in the clinical score group (hazard ratio 1.30,
95% confidence interval 1.03 to 1.63), equivalent to saving a
day of moderately bad symptoms. Resolution was faster in the
antigen test group but not significantly (table 2⇓).
Use of antibiotics
Of the patients in the delayed prescribing group, 46% (74/164)
reported using antibiotics. The other two groups had a lower
use of antibiotics: compared with the delayed prescribing group
there was an estimated 29% relative reduction in the clinical
score group (risk ratio 0.71, 0.50 to 0.95) and a 27% relative
reduction in the antigen test group (0.73, 0.52 to 0.98; table 2⇓).
Belief in need to see doctor in future
There was a trivial difference in belief in the need to see a
doctor, treated either as a continuous variable or dichotomised
(table 2⇓).
Return to the surgery
There were no significant differences in return to the surgery
during the following month or the subsequent follow-up.
Suppurative complications
There were no suppurative complications (otitis media, sinusitis,
quinsy, or cellulitis) in either phase of the trial. Fewer than 1%
of patients returned with either skin rash or diarrhoea within a
month of the index consultation in any group for score 2
(delayed prescribing 0/207, clinical score 2/210, antigen test
1/211), with similar findings for score 1 (delayed prescribing
5/374; clinical score 0/380; antigen test 1/359).
Compliance with prescribing strategy
Table 1 also shows the prescribing strategy used at the baseline
consultation and shows that groups were well differentiated⇓.
As this was a pragmatic trial clinicians were asked to use the
intended strategy when this could be agreed with the patient but
were given flexibility to negotiate other strategies, as would
happen in practice. The intended strategy occurred in 83% of
consultations (520/629): 79% (162/205) in the delayed group,
85% (179/211) in the clinical score group, and 179/213 (84%)
in the antigen test group. Compliance with the intended
strategies was also good for score 1 (see appendix 1, table B).
Selection and attrition bias, practice effects
There was no evidence of clinical selection bias when we
compared the patients in the two parts of the trial (appendix 3).
Although the trial patients presented with slightly fewer
streptococcal features compared with observational cohorts,
when we selected practices recruiting patients with higher
streptococcal scores the estimates of effect were larger, which
suggests the trial results are possibly conservative.
Adjustment for practice as a covariate (that is, for potential
confounding) provided similar estimates and inferences, whereas
adjustment for clustering by practice resulted in slightly different
inferences (table 3⇓).
Discussion
Principle findings
Our results suggests that across a range of practitioners and
practices, use of either a simple clinical score or a clinical score
with a rapid antigen test is likely to moderately improve
symptom control and reduce antibiotic use. Use of the clinical
score combined with targeted use of a rapid antigen test provided
similar benefits but with no clear advantages compared with
use of a clinical score alone.
Main results in context of previous literature
Although the effect on symptom severity in the antigen test
group did not quite reach the minimum clinical difference
specified in advance nor statistical significance, the effect in
both antigen test and clinical score groups was similar—tomake
a difference of one person in three rating sore throat a slight
problem rather than a moderately bad problem. Both
interventions also reduced antibiotic use. Compared with use
of the clinical score alone, however, there was no evidence
either for symptom management or antibiotic use to justify the
increased time (five minutes) and costs of using rapid antigen
tests. The limited additional value of a rapid antigen test might
be because the diagnostic advantage in such tests in identifying
group A streptococci is in part matched by the disadvantage of
not identifying group C and G streptococci, which provide
similar symptom burdens to group A organisms. The previous
small trial of rapid antigen tests10 showed that using the Centor
score23 24with or without antigen tests on its own did not modify
antibiotic use, but symptomatic outcomes were not reported.
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The difference between these trials could be that in our trial we
used amore reliable score: we have shown that individual items
from the Centor score and score 1 did not perform optimally in
our two previous diagnostic cohorts in terms of identifying
patients with low likelihood of streptococcal infection. It is
possible that a more liberal use of rapid antigen tests (for
example, for patients with a FeverPAIN score of 2 or more
rather than ≥3) would result in less use of antibiotics, but our
initial health economic modelling suggested that using rapid
antigen tests for those with lower risks of streptococcal infection
would be more inefficient, and interviews with practitioners
suggested that more widespread use of near patient tests would
be unacceptable. It is unclear why symptommanagement should
be significantly better with score 2 than score 1. Possibly the
particular combinations of more florid symptoms in score 2
(such as fever and pus, which are not in score 1) are more
important in determining symptom burden, and/or better in
determining symptom response to antibiotics because of
microbiological or patient factors (such as the differential nature
of organisms on the surface and in the crypts of the tonsils or
the relation between symptoms, the immune response, and
prognosis25 26). Possibly score 2 has greater clinical face validity
for clinicians or patients, which could perhaps facilitate stronger
advocacy and potentially better adherence to the proposed
prescribing strategy, although our relatively crude data
concerning what health professionals did (but acknowledging
that we do not know how they did it) suggest health
professionals complied reasonably well with the proposed
prescribing strategies.
The rate of antibiotic use reported in the current trial with
delayed prescribing (>40%) was significantly higher than our
previous research,5 17 but the number of features associated with
streptococcal infection was also higher (for example, 15% had
purulent tonsils in the previous trial compared with 26% in this
trial), so it could be that more patients with milder sore throats
are now self caring rather than consulting their general
practitioner compared with 15 years ago. The previous trial also
recruited predominantly in deprived inner city settings, whereas
the current trial had a wider range of practices.
We could not show any difference in belief in the need to see
a doctor or reconsultations either within a month or with longer
follow-up—that is, no apparent “medicalising” effect of the
rapid antigen test strategy. This compares with a dramatic
medicalising effect of prescribing antibiotics.12 17 The lack of
an effect with rapid antigen testing in a trial setting where such
tests are not used routinely, however, might mean that it is
difficult to show medicalisation in the short term. Longer term
implementation studies or possibly international comparison
studies might be needed.
Strengths and weaknesses
To our knowledge this is the first randomised trial to assess the
impact of rapid antigen detection tests and clinical scoring
methods on both symptom control and antibiotic use for acute
sore throat, one of the commonest respiratory infections
managed in clinical practice. The FeverPAIN phase of the trial
provided limited power to assess dichotomous outcomes but
had adequate power for symptomatic outcomes. Groups were
slightly unbalanced for fever, but we documented estimates
adjusted for fever, and, in other respects, trial groups were
similar. Symptomatic outcomes and antibiotic use changed
significantly in the expected direction for both intervention
groups, suggesting chance is an unlikely explanation. The trial
was designed and analysed as an individually randomised trial,
but practice variation probably makes a modest difference:
adjustment for practice as a covariate did not alter the inferences,
and adjustment for clustering by practice led to slightly reduced
significance for symptom severity in the clinical score group
but slightly increased significance for symptom resolution.
Information about non-recruitment was poor, as would be
expected for a trial recruiting acutely unwell patients during
clinics at the busiest times of year. Streptococcal scores were
slightly lower in the trial compared with previous observational
studies, but differences were modest (15% lower), and exclusion
of practices with low scores increased the estimates, which
suggests the trial results are conservative. This was a pragmatic
trial so clinicians could negotiate management, as happens in
everyday practice. Nevertheless compliance with the intended
intervention was good, and the results for score 2 cannot be
explained by greater compliance as compliance for score 1 was
as good. Clinicians used management prompts for the clinical
score based on history and examination, so it is unclear whether
clinicians not using such prompts would achieve similar results.
Implications for practice and future research
Clinicians can consider using a clinical score to target antibiotic
use for acute sore throat, which is likely to reduce antibiotic use
and improve symptom control. There is no clear advantage in
additional use of a rapid antigen detection test. As two
examination components are required for the clinical score the
validity for telephone triage is unclear. Although previous
duration of illness (rapid attendance in three days or less) could
reflect health system factors, the same variable was equally
important in a different health system with different
expectations.27 As rapid attendance probably reflects the speed
of progression of symptoms, it would also be helpful to compare
other methods of operationalising this variable in other settings.
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What is already known on this topic
Antibiotics are still prescribed for most patients attending primary care with acute sore throat
Rapid antigen detection tests and clinical scores are commonly used to target antibiotic use, but there is little robust trial evidence to
support their use
What this study adds
Compared with empirical delayed antibiotic prescribing for acute sore throat, use of a clinical score improves both reported symptoms
and antibiotic use
Use of the clinical score combined with targeted use of a rapid antigen test provides similar benefits but with no clear advantages
compared with use of a clinical score alone
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Tables
Table 1| Clinical assessment and prescribing strategy used by general practitioners at baseline consultation in patients presenting with
sore throat. Figures are numbers (percentage) unless stated otherwise
Group 3 (clinical score + rapid
antigen test)Group 2 (clinical score only)
Group 1 control (delayed
prescription)Clinical assessment
3.2 (0.71)3.2 (0.72)3.2 (0.72)Mean (SD) severity of sore throat/difficulty
swallowing on 4 point Likert scale
5.0 (4.6)4.5 (3.8)4.9 (3.9)Mean (SD) previous duration (days)
29(17)31 (17)29 (16)Mean (SD) age (years)
138/212 (65)127/210 (60)139/207 (67)Female
44/212 (21)39/210 (19)31/207 (15)Smoker
112/212 (53)135/211 (64)111/207 (54)Fever in past 24 hours
36.9 (0.69)36.9 (0.70)37.0 (0.72)Mean (SD) temperature (°C)
53/212 (25)56/210 (27)54/206 (26)Pus on tonsils
Strategy used by clinician:
126/213 (59)87/211 (41)21/207 (10)Antibiotics not offered
38/213 (18)33/211(16)21/207 (10)Immediate antibiotics
48/213 (23)91/211 (43)164/207 (79)Delayed antibiotics
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Table 2| Symptom severity, antibiotic use, intention to consult in future (moderately likely or more likely), and reconsultations with sore
throat (95% confidence intervals) in patients with sore throat according to randomised group
Group 3 (clinical score + rapid antigen test)Group 2 (clinical score only)Group 1 control (delayed prescription)
Mean severity of sore throat and difficulty swallowing days on days 2-4 (7 point scale: 0 = no problem, 6 as bad as it could be):
2.83 (1.62)2.88 (1.52)3.11 (1.49)Crude mean (SD)
−0.30 (−0.61 to 0.004; P=0.05)−0.33 (−0.64 to −0.02; P=0.04)—Adjusted mean difference*
Duration of symptoms rated moderately bad or worse (days):
4 (2-7)4 (2-6)5 (3-7)Median duration (IQR)
1.11 (0.88 to 1.40; P=0.37)1.30 (1.03 to 1.63; P=0.03)1.00Hazard ratio*
Antibiotic use:
58/164 (35%)60/161 (37%)75/164 (46%)Crude percentage
0.73 (0.52 to 0.98; P=0.03)0.71 (0.50 to 0.95; P=0.02)1.00Risk ratio*
Belief in need to see doctor in future episodes (slightly likely or less):
64/161 (40%)54/155 (35%)62/163 (38%)Crude percentage
1.03 (0.76 to 1.32; P=0.86)0.97 (0.71 to 1.27; P=0.85)—Risk ratio*
Return within 1 month with sore throat:
13/212 (6%)17/210 (8%)17/207 (8%)Crude percentage
0.74 (0.36 to 1.47; P=0.400.91 (0.47 to 1.72; P=0.781.00Risk ratio*†
Return after 1 month with sore throat (mean follow-up 0.73 years):
34/211 (16%)26/210 (12%)31/207 (15%)Crude percentage
1.06 (0.66 to 1.63; P=0.810.79 (0.47 to 1.29; P=0.351.00Risk ratio*‡
*All models adjusted for baseline symptom severity (of sore throat and difficulty swallowing) and fever during previous 24 hours
†Additionally adjusted for previous antibiotic use.
‡Additionally adjusted for previous attendance with sore throat and duration of follow-up.
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Table 3| Effect on outcomes of additional adjustment for practice as covariate and clustering by practice in patients with sore throat
according to randomised group (group group 2 was clinical score only, group 3 was clinical score plus rapid antigen test)
Additional adjustment
Adjusted for baseline symptom severity and fever Clustering by practicePractice as covariate
Mean symptom score
−0.33 (−0.70 to 0.05; P=0.08)−0.33 (−0.64 to −0.02; P=0.04)−0.33 (−0.64 to −0.02; P=0.04)Group 2
−0.30 (−0.74 to 0.13; P=0.16)−0.31 (−0.62 to 0.007; P=0.06)−0.30 (−0.61 to 0.004; P=0.05)Group 3
Symptom resolution*
1.30 (1.07 to 1.57; P=0.01)1.29 (1.02 to 1.63; P=0.03)1.30 (1.03 to 1.63; P=0.03)Group 2
1.11 (0.86 to 1.43; P=0.42)1.11 (0.88 to 1.40; P=0.38)1.11 (0.88 to 1.40; P=0.37)Group 3
Antibiotic use†
0.71 (0.51 to 0.93; P=0.01)0.68 (0.48 to 0.94; P=0.02)0.71 (0.50 to 0.95; P=0.02)Group 2
0.73 (0.51 to 1.00; P=0.05)0.70 (0.49 to 0.95; P=0.02)0.73 (0.52 to 0.98; P=0.03)Group 3
*Hazard ratio.
†Risk ratio.
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Figure
CONSORT trial flow diagram for second phase of trial with score 2 (FeverPAIN). *Approximate estimates based on report
by recruiting health professional
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